Related Experiment Video
Updated: Mar 26, 2026
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
Published on: November 24, 2014
Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01
Beatriz Vera1,2,3, Naiara Martínez-Vélez1,2,3, Enric Xipell1,2,3
1Navarra's Health Research Institute (IDISNA) Pamplona, Spain.
Abstract:
Despite the recent advances in the development of antitumor therapies, the prognosis for patients with malignant gliomas remains dismal. Therapy with tumor-selective viruses is emerging as a treatment option for this devastating disease. In this study we characterize the anti-glioma effect of VCN-01, an improved hyaluronidase-armed pRB-pathway-selective oncolytic adenovirus that has proven safe and effective in the treatment of several solid tumors. VCN-01 displayed a significant cytotoxic effect on glioma cells in vitro. In vivo, in two different orthotopic glioma models, a single intra-tumoral administration of VCN-01 increased overall survival significantly and led to long-term survivors free of disease.
Insights
VCN-01, a novel oncolytic adenovirus, shows significant promise in treating malignant gliomas. This therapy effectively reduced glioma cells in vitro and improved survival in preclinical models.
Area of Science:
- Oncolytic virotherapy
- Gene therapy
- Cancer research
Background:
- Malignant gliomas have a poor prognosis despite advances in antitumor therapies.
- Oncolytic viruses are an emerging treatment strategy for aggressive cancers.
- VCN-01 is an oncolytic adenovirus engineered for tumor selectivity and enhanced efficacy.
Purpose of the Study:
- To evaluate the anti-glioma efficacy of VCN-01.
- To characterize the in vitro and in vivo effects of VCN-01 on glioma models.
- To assess the potential of VCN-01 as a therapeutic agent for malignant gliomas.
Main Methods:
- In vitro cytotoxicity assays on glioma cell lines.
- In vivo studies using two orthotopic glioma models in animals.
- Intra-tumoral administration of VCN-01.
Main Results:
- VCN-01 demonstrated significant cytotoxic effects against glioma cells in vitro.
- A single intra-tumoral dose of VCN-01 significantly increased overall survival in vivo.
- Long-term, disease-free survival was observed in treated animals.
Conclusions:
- VCN-01 exhibits potent anti-glioma activity.
- VCN-01 represents a promising therapeutic candidate for malignant glioma treatment.
- Further clinical investigation of VCN-01 for glioma is warranted.
Related Concept Videos
01:27Cytomegalovirus Disease
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...